Laekna Inc. has announced the commencement of a Phase I multiple dose expansion study of LAE102 for the treatment of obesity in China. The study is a randomized, double-blind, placebo-controlled trial involving 60 overweight or obese subjects, who will receive either LAE102 or placebo over a six-month period. The primary objectives are to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE102. This trial follows positive one-month results from an earlier multiple ascending dose (MAD) study. Results from the current study have not yet been presented and will be available in the future.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251222-11962878), on December 22, 2025, and is solely responsible for the information contained therein.